Meta description: Regulatory update on a completed pediatric high myopia trial that combines low dose atropine with soft peripheral defocus lenses, offering insight for device and drug evaluation.
On February 15 2026 a record from ClinicalTrials.gov describes a study sponsored by Beijing Tongren Hospital. The trial centers on children with high myopia and uses a mixed approach that includes a device element and a drug element. The key components listed are soft peripheral defocus contact lenses, atropine 0.04 percent and atropine 0.01 percent, and single vision spectacles. The record notes the study is listed as completed.
In this article the implications for regulation and clinical practice are explored. The frame for interpretation rests on what the record shows and what it does not show in terms of results. The source text suggests the existence of multiple intervention components and a site in China, which has bearing on how results may be reviewed in various jurisdictions.
In this article
- What changed
- What is the study scope
- What interventions are involved
- What are the regulatory implications
- Who is affected
- What comes next
- FAQ
- Conclusion
- Disclaimer
- Announcement link
What changed?
The record describes a completed trial that uses a combination approach involving a device and a drug. The source text does not provide efficacy or safety results. It confirms the existence of multiple intervention components and a defined patient population.
What is the study scope?
The conditions listed are high myopia in children. The interventions include a device type soft peripheral defocus contact lenses, two drug concentrations of atropine, and a device described as single vision spectacles. The aim appears to be to slow progression of myopia in pediatric patients.
What interventions are involved?
- Device: soft peripheral defocus contact lenses
- Drug: Atropine 0.04 percent
- Drug: Atropine 0.01 percent
- Device: Single vision spectacles
What are the regulatory implications?
Mixed use trials can involve distinct clearance pathways for devices and drugs. The record shows a device oriented approach combined with a topical medication. The sponsor Beijing Tongren Hospital may influence how results are viewed in different markets and how safety data are interpreted.
Who is affected?
The primary population is children with high myopia. The information may be relevant to clinicians, researchers and regulators evaluating combination product strategies. The record does not provide patient level outcomes.
What comes next?
Future steps include publication of results and regulatory submissions if efficacy and safety are demonstrated. Regulators will review the device and the drug components for appropriate classification and labeling. The official trial page provides the primary source for this information.
FAQ
- What is being tested in this trial
- Who sponsors the trial
- Is there efficacy data in the source text
The study tests a combined approach using a device and drugs to control myopia progression in children with high myopia
The sponsor is Beijing Tongren Hospital
No efficacy results are provided in the source text
Conclusion
In summary the record shows a completed trial of a combined low concentration atropine and soft lens approach for pediatric high myopia. Regulators will consider how device and drug components are classified and how results should be reported. This update supports ongoing monitoring of combined therapy strategies in pediatrics.
Disclaimer
This information is intended for professionals and is not legal advice. It reflects the source text and does not replace regulatory guidance.
Announcement line
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07406399?term=medical+device